Winning Health(SZ:300253) Mei Ri Jing Ji Xin Wen·2025-11-06 08:41Core Viewpoint - The recent bribery case involving the chairman of Weining Health and its subsidiary has raised significant concerns regarding corporate governance and internal controls, leading to a notable decline in investor confidence and market image [1][2]. Financial Performance - Shenzhen Weining Zhongtian achieved revenues of 23.68 million yuan in 2022, 15.64 million yuan in 2023, and 13.65 million yuan in 2024, representing a small proportion of the overall revenue of the listed company [2]. - For the first three quarters of 2025, Weining Health reported revenues of 1.296 billion yuan and a net loss attributable to shareholders of 241 million yuan, indicating a challenging overall operational status [2]. Corporate Governance and Compliance - The bribery incident highlights serious flaws in Weining Health's corporate governance and internal supervision, necessitating the establishment of robust internal monitoring mechanisms to enhance transparency and effectiveness [2]. - The company is urged to strengthen compliance with laws and regulations to mitigate legal risks and reputational damage [2]. Risk Management and Communication - Weining Health should improve its information disclosure practices to ensure timely, accurate, and complete communication of significant matters to maintain market confidence [2]. - The company needs to enhance risk management strategies to assess and manage potential internal and external risks that could impact operations [2]. Industry Implications - The bribery case serves as a warning to the entire listed company sector, emphasizing the need for strict regulation and effective legal measures to curb illegal activities and ensure the long-term health of the capital market [3].